Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Top 5 Stocks in Larry Robbins’ Portfolio

In this article, we will discuss top 5 stocks in Larry Robbins portfolio. If you want to read the detailed analysis of Robbins’ investment philosophy, net worth, and performance go directly to Larry Robbins Net Worth, Performance and Portfolio.

5. DXC Technology Co (NYSE:DXC)

Number of Hedge Fund Holders:23
Percentage of Glenview Capital’s Portfolio:5.02%

Together and its subsidiaries, DXC Technology Co (NYSE:DXC) offers information technology services and solutions while operating through two segments of Global Business Services and Global Infrastructure Services. The company delivers a full suite of Oracle Cloud Solutions and services as part of its effort to deliver innovative application services for accelerating business transformation.

After coming under immense pressure in the first half of the year, the stock has recouped all the losses and showing signs of edging higher. Glenview Capital holds 8.9 million shares in DXC Technology Co (NYSE:DXC), which is worth over $228.94 million, representing 5.02% of its portfolio.

At the end of Q1 2023, 23 hedge funds owned a stake in DXC Technology Co (NYSE:DXC), down from 31 in the preceding quarter.

Follow Dxc Technology Co (NYSE:DXC)

4. Global Payments Inc (NYSE:GPN)

Number of Hedge Fund Holders:56
Percentage of Glenview Capital’s Portfolio:5.18%

Global Payments Inc. (NYSE:GPN), a provider of payment technology and software solutions, has benefited from the boom in the financial sector. The stock is already up by more than 8% for the year as it bounces back after a long period of consolidation. While operating through three segments: Merchant Solutions, Issuer Solutions, and Consumer Solutions, it pays a solid dividend yield of 0.92%

Securities filings reveal that Glenview Capital trimmed its stake in Global Payments Inc. (NYSE:GPN) by 7% during the first quarter of 2023. The fund presently owns 2.24 million shares of Global Payments Inc. (NYSE:GPN) worth over $236.18 million, representing 5.18% of the portfolio.

According to Insider Monkey’s database, 56 hedge funds were long Global Payments Inc (NYSE:GPN) as of Q1 2023. The total value of their holdings was $2.66 billion. Orbis Investment Management is a significant shareholder in the company, with 6.55 million shares valued at $689 billion.

Barclays analyst Ramsey El-Assal lifted the firm’s price target on Global Payments Inc. (NYSE:GPN) from $125 to $135 and reiterated an ‘Overweight’ rating on the stock on July 10.

Oakmark Funds made the following comment about Global Payments Inc. (NYSE:GPN) in its Q4 2022 investor letter:

“We eliminated four positions during the quarter: Philip Morris International, ConocoPhillips, Global Payments Inc. (NYSE:GPN) and Johnson Controls. We sold Global Payments to utilize a tax loss and to increase our position in Fiserv, a similar business that offers better fundamentals at a comparable valuation.”

Follow Global Payments Inc (NYSE:GPN)

3. Fiserv Inc (NASDAQ:FISV)

Number of Hedge Fund Holders:64
Percentage of Glenview Capital’s Portfolio:5.33%

Headquartered in Brookfield, Wisconsin, Fiserv Inc (NASDAQ:FISV) has carved a niche in offering financial technology services to clients across the financial services sector, including banks, credit unions, and security brokers. It also provides technology infrastructure that allows merchants to accept card payments.

Fiserv Inc (NASDAQ:FISV) is up by more than 24% for the year benefiting from the easing of pressure in the financial sector and the high-interest rate environment that has made banks’ stocks and the entire sector attractive.

Glenview Capital holds 2.15 million shares in Fiserv Inc (NASDAQ:FISV), which is worth over $243.10 million, representing 5.33% of its portfolio.

According to Insider Monkey’s database, 64 hedge funds owned stakes in the company at the end of the first quarter, down from 65 in the preceding quarter. Harris Associates held the biggest stake in Fiserv Inc (NASDAQ:FISV) at the end of Q1 2023 with 17.36 shares.

Renaissance Investment Management made the following comment about Fiserv, Inc. (NASDAQ:FISV) in its Q4 2022 investor letter:

“We made one change to the portfolio in the fourth quarter, adding a new position in the Information Technology sector with Fiserv, Inc. (NASDAQ:FISV), a leading financial services technology company that facilitates the movement of money, helping to run the financial operations of banks and merchants. The company enjoys a leading market position in a rational oligopoly in which the top three companies control 70% of the entire market. We also like the company’s strategy of being a “one-stop-shop” for banks and merchants, resulting in a large financial platform that has the operating scale to outcompete smaller rivals and a recurring revenue model that is highly attractive in uncertain macroeconomic environments.”

Follow Fiserv Inc (NASDAQ:FISV)

2. Tenet Healthcare Corp (NYSE:THC)

Number of Hedge Fund Holders:66
Percentage of Glenview Capital’s Portfolio:9.47%

Tenet Healthcare Corp (NYSE:THC), a diversified healthcare service company operating through three segments of hospital operations, ambulatory care, and conifer, has been among the best-performing stocks. It’s already up by more than 60%, outperforming the S&P 500, that’s up by about 15%.

The solid performance stems from the company completing several acquisitions and forming strategic partnerships that have helped scale the business operating capacity and geographical footprint. Mizuho maintained a ‘Buy’ rating on Tenet Healthcare Corp (NYSE:THC) and increased its price target to $94 on July 11.

Larry Robbins’ Glenview Capital held a significant stake in Tenet Healthcare Corp (NYSE:THC) at the end of Q1 2023. According to the 13F filings for the first quarter of 2023, the Larry Robbins stock portfolio had 7.27 million shares of Tenet Healthcare Corp (NYSE:THC), worth $431.84 million and representing 9.47% of the total holdings.

At the end of the first quarter of 2023, 66 hedge funds owned a stake in Tenet Healthcare Corp (NYSE:THC), up from 59 in the preceding quarter.

Greenlight Capital made the following comment about Tenet Healthcare Corporation (NYSE:THC) in its Q4 2022 investor letter:

“Though we believe we are in the middle stages of a bear market, we did establish a new medium-sized long position in Tenet Healthcare Corporation (NYSE:THC) during the fourth quarter.

THC is an operator of hospitals and ambulatory surgery centers (ASC). In recent years, the company has grown and transitioned its business mix towards its higher-margin ASCs. This shift has enabled the company to generate significant, and what we believe to be sustainable, cash flows.

During 2022, the company lowered its guidance due to COVID and inflationary headwinds, resulting in its shares declining by more than 50% year-to-date through late October. We believe this pullback offered an attractive opportunity to participate in the company’s transformation, as we expect its ASC growth to remain strong and its now smaller hospital portfolio to improve from both a cost and volume perspective. We acquired our shares from late December through the beginning of January for an average price of $48.61, or 8.7x 2023 consensus earnings. THC recently announced and began its plan to repurchase about 20% of the outstanding shares by the end of 2024.”

Follow Tenet Healthcare Corp (NYSE:THC)

1. Cigna Group (NYSE:CI)

Number of Hedge Fund Holders:79
Percentage of Glenview Capital’s Portfolio:10.37%

Cigna Group (NYSE:CI) is one company that provides insurance and other related products and services in the US. It also offers coordinated and point-solution health services, including pharmacy benefits, care delivery, and management solutions to health plans.

While the stock is down by about 10% for the year, it has started bouncing back, rallying by more than 11% since June lows. Based on 6 buy ratings, 7 hold ratings and 0 sell ratings, Cigna Group (NYSE:CI) has a consensus rating of ‘Moderate Buy.’

Securities filings reveal that Glenview Capital increased its stake in Cigna Group (NYSE:CI) by 1% during the first quarter of 2023. The fund presently owns 1.85 million shares of Cigna Group (NYSE:CI) worth over $472.89 million, representing 10.37% of the portfolio.

The number of hedge funds tracked by Insider Monkey having stakes in Cigna Group (NYSE:CI) grew to 79 in Q1 2023, from 76 in the preceding quarter. Citadel Investment Group is the leading shareholder of Cigna Group (NYSE:CI), with 2.04 million shares worth over $520.40 million.

ClearBridge Investments mentioned The Cigna Group (NYSE:CI) in its investor letter for the first quarter of 2023, stating the following:

“At the same time, we exited health insurance company The Cigna Group (NYSE:CI), whose strong outperformance over the last year has resulted in shares trading at a significant premium relative to competitor CVS Health. Additionally, we view CVS Health’s underperformance as driven by temporary issues and believe it has a good likelihood of succeeding in its improvement initiatives following upgrades to the management team and its acquisition of Oak Street Health. As a result, we elected to swap our position in Cigna into CVS Health to capitalize on the valuation gap while maintaining similar exposure within the sector.”

Follow Cigna Group (NYSE:CI)

Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily newsletter to get  the latest investment ideas from hedge funds’ investor letters by entering your email address below. You can also check out our articles on Billionaire Investor Who Returned 51% in 2022 is Selling These 12 Stocks in 2023 and George Soros’ Top 10 Stock Picks.

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard.

Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences.

At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000.

Do the math. According to Musk, this technology could be worth $250 trillion by 2040.

Put another way, that’s roughly equal to:

  • 175 Teslas
  • 107 Amazons
  • 140 Metas
  • 84 Googles
  • 65 Microsofts
  • And 55 Nvidias

And here’s the wild part — this $250 trillion wave isn’t tied to one company, but to an entire ecosystem of AI innovators set to reshape the global economy.

It’s a leap so massive, it could reshape how businesses, governments, and consumers operate worldwide.

Even if that $250 trillion figure sounds ambitious, major firms like PwC and McKinsey still see AI unlocking multi-trillion-dollar potential.

How could anything be worth that much?

The answer lies in a breakthrough so powerful it’s redefining how humanity works, learns, and creates.

And this breakthrough has already set off a frenzy among hedge funds and Wall Street’s top investors.

What most investors don’t realize is that one under-owned company holds the key to this $250 trillion revolution.

In fact, Verge argues this company’s supercheap AI technology should concern rivals.

Before I reveal the details, let’s talk about how some of the richest people on the planet are positioning themselves.

  • Bill Gates sees artificial intelligence as the “biggest technological advance in my lifetime,” more transformative than the internet or personal computer, capable of improving healthcare, education, and addressing climate change.
  • Larry Ellison — through Oracle, is spending billions on Nvidia chips and partnering with Cohere to embed generative AI across Oracle’s cloud and apps.
  • Warren Buffett — not known for tech hype — says this breakthrough could have a ‘hugely beneficial social impact.

When billionaires from Silicon Valley to Wall Street line up behind the same idea — you know it’s worth paying attention to.

Even as we admire what Tesla, Nvidia, Alphabet, and Microsoft have built, we believe an even greater opportunity lies elsewhere…

But the real story isn’t Nvidia — it’s a much smaller company quietly improving the critical technology that makes this entire revolution possible.

And judging by what I’m hearing from both Silicon Valley insiders and Wall Street veterans…

This prediction might not be bold at all:

A few years from now, you’ll wish you’d owned this stock.

The best part? You can discover everything about this company and its groundbreaking technology right now.

I’ve compiled everything you need to know about this groundbreaking company in a detailed, members-only report.

Trust me — you’ll want to read this report before putting another dollar into any tech stock.

For a ridiculously low price of just $9.99 a month, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s what to do next:

1. Subscribe to our Premium Readership Newsletter for just $9.99 a month. (33% Off – was $14.99).

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

<b>Cancel anytime.</b> Turn off auto-renewal via our website with just a click.

 

Buy This $3 Stock Now Before the 400% Surge Begins

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

My name is Inan Dogan. I’m the co-founder and Research Director of Insider Monkey. I have an important message for you today.

Since March 2017, my stock picks have returned 16.5% annually. Today, I’ve found an opportunity even bigger than my British American Tobacco call.

Two years ago, Wall Street wrote off British American Tobacco (BTI) as a “melting ice cube.” The stock had crashed 40% from its peak, and consensus said the business was dying.

We looked under the cover and realized they were wrong.

We alerted our subscribers, and BTI returned 90% in just 16 months.

Now if you had invested just $10,000 in BTI in June 2024, you’d be sitting on $19,000 in October 2025.

Today, we have identified a nearly identical pattern in a digital-first giant trading at $3.

While the market panics over a surface-level revenue decline, our PhD-led research shows management has actually surgically cut $100 million in waste to focus on high-margin growth.

This pattern is a hallmark of our 16.5% annual return track record. The current opportunity offers a 400% upside potential—dwarfing even our 90% BTI return.

Get the ticker for our new “Underdog” pick and the full BTI case study for just 99 cents.

This exclusive offer is for NEW newsletter subscribers ONLY! Join our Premium Readership Newsletter for only $0.99 and become part of a savvy investor community.!

This offer vanishes in 7 days, so don’t miss your chance to lock in market beating returnsSign up NOW! The monthly newsletter comes with a 30-day, no-risk money-back guarantee. This offer is available to the first 1000 new investors who respond.

Regular price $9.99/mo. Cancel anytime.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $0.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Regular price $9.99/mo. Cancel anytime.